Xuanzhu Biopharmaceutical Co., Ltd. (HKG:2575)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
66.00
+0.55 (0.84%)
At close: Feb 27, 2026
124.03%
Market Cap 34.18B
Revenue (ttm) 35.02M
Net Income (ttm) -609.65M
Shares Out 517.95M
EPS (ttm) -1.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 365,311
Average Volume 333,383
Open 65.00
Previous Close 65.45
Day's Range 64.90 - 68.00
52-Week Range 23.82 - 96.90
Beta n/a
RSI 50.47
Earnings Date n/a

About Xuanzhu Biopharmaceutical

Xuanzhu Biopharmaceutical Co., Ltd. engages in the development, industrialization, and commercialization of small-molecule chemical drugs and macromolecular biopharmaceuticals in China. Its lead product candidates include Core- KBP-3571 for the treatment of duodenum ulcers; XZP-3287, a CDK4/6 inhibitor for the treatment of HR+/HER2 advanced breast cancer; and XZP-3621, a first-line treatment for patients with anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. The company also develops KM501, a first-in-class HER2/HER2 bisp... [Read more]

Sector Healthcare
Founded 2008
Employees 197
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2575
Full Company Profile

Financial Performance

In 2024, Xuanzhu Biopharmaceutical's revenue was 30.09 million, an increase of 103672.41% compared to the previous year's 29,000. Losses were -556.43 million, 85.1% more than in 2023.

Financial numbers in CNY Financial Statements

News

There is no news available yet.